Postoperative Delirium
Conditions
Interventions
Single Bolus Group (SB):The SB group received a 30-minute infusion of placebo (normal saline) prior to the start of surgery
during induction of anesthesia, S-ketamine was administered as a single intravenous bolus of 0.2 mg/kg within 30 - 60 seconds after all induction drug infusions had been completed.Placebo (normal sali
Single Bolus plus Intraoperative Continuous Infusion Group (SBCI):The SBCI group received a 30-minute infusion of placebo (normal saline) prior to the start of surgery
during induction of anesthesia, S-ketamine was administered as a single intravenous bolus of 0.2 mg/kg within 30 - 60 seconds after all induction drug infusions had been completed. S-ketamine was infu
Preoperative Pre-infusion plus Postoperative Continuous Infusion Group (PICI):The PICI group received S-ketamine 0.1 mg/kg prior to the start of surgery, infused over 30 minutes (equivalent to 0.2 mg/
Sponsors
The Affiliated Hospital of Qingdao UniversityThe Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 60 years. 2.Scheduled to undergo elective non-cardiac, non-neurosurgical surgery under general anesthesia, with an expected surgical duration of at least 2 hours (e.g., gastrointestinal surgery, hepatobiliary and pancreatic surgery, otorhinolaryngologic surgery, lower limb joint arthroplasty, spinal surgery, thoracic surgery, urologic surgery, gynecologic surgery). 3.Planned use of patient-controlled intravenous analgesia (PCA) for postoperative pain management. 4.Provision of written informed consent.
Exclusion criteria
Exclusion criteria: 1.Pre-existing delirium state or psychotic disorder at time of screening. 2.Known contraindications to S-ketamine: documented allergy or hypersensitivity; intracranial aneurysm; uncontrolled hyperthyroidism; glaucoma. 3.Severe cardiovascular disease: grade III hypertension, unstable angina pectoris, severe valvular heart disease, severe arrhythmia (e.g., uncontrolled atrial fibrillation), or severe macrovascular disease. 4.Severe hepatic or renal impairment: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2N upper limit of normal; hyperbilirubinemia; prothrombin time = 3.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of POD; | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of delirium;The onset time of delirium;The duration of delirium;Delirium severity score;Subtypes of delirium;Pain scores at rest and exercise;Opioid consumption;Sleep quality score;Quality of recovery score; | — |
Countries
China
Contacts
Public ContactLei Zhang
The Affiliated Hospital of Qingdao University
Outcome results
None listed